Ginkgo Bioworks Holdings, Inc.
DNA· NYSE
Released Feb 26, 2026, after the close
10-K filed Feb 26, 2026, 57 days after period end · 0001628280-26-012346
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $63.41M | $43.85M | $34.76M | $98.29M |
| Net Income | -$80.75M |
Ginkgo Bioworks Holdings, Inc. · CIK 1830214 · Engraved from SEC EDGAR
| -$107.53M |
| -$211.69M |
| -$175.47M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.